Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Scott J Antonia"'
Autor:
Hong Zheng, Uzma Khan, Xiaofei Wang, Xiaoqing Yu, Georgia M Beasley, James Ronald, Jhanelle E Gray, Scott J Antonia, Steven Wolf, Neal E Ready, Bruna Pellini, Andreas N Saltos, Christy Arrowood, Ghassan El-Haddad, Tawee Tanvetyanon, Luiziane Guerra-Guevara, Lin Gu, Dana Foresman, Mark J Cantwell, Amer A Beg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/105d880a19504b1fae2902e604088ef5
Autor:
Raffit Hassan, Patrick M Forde, Edward B Garon, Steven M Dubinett, Roy S Herbst, Charu Aggarwal, Matthew D Hellmann, Sarah B Goldberg, David L Rimm, Sarah Sagorsky, Boris Sepesi, Ramaswamy Govindan, Andrea Ferris, Scott J Antonia, Fred R Hirsch, Lawrence H Schwartz, Marianne Davies, Melissa L Johnson, Shakun Malik, Daniel Morgensztern, Joel W Neal, Jyoti D Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 5 (2022)
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibito
Externí odkaz:
https://doaj.org/article/a7041ff7bb174ceaaf1394ae132d1c32
Autor:
Mustafa Khasraw, Susan M Chang, Amy B Heimberger, Michael Lim, John Simes, Solmaz Sahebjam, Michael Platten, Wolfgang Wick, David M Ashley, Patrick Y Wen, Aaron C Tan, Stephen J Bagley, Howard Colman, Evanthia Galanis, Alireza Mansouri, Simon Khagi, Minesh P Mehta, Vinay K Puduvalli, Scott J Antonia, Don Berry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel–novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the
Externí odkaz:
https://doaj.org/article/5fb3fb4dbf464e6b9e23b9714b84f3ae
Publikováno v:
APL Bioengineering, Vol 8, Iss 1, Pp 016120-016120-11 (2024)
Perfusable microvascular networks offer promising three-dimensional in vitro models to study normal and compromised vascular tissues as well as phenomena such as cancer cell metastasis. Engineering of these microvascular networks generally involves t
Externí odkaz:
https://doaj.org/article/2835ef51e4c44031a89f6c901b0cfcee
Autor:
Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a
Externí odkaz:
https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d
Autor:
Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100337- (2022)
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatmen
Externí odkaz:
https://doaj.org/article/4e8e10cbb46b4c6b9961babf7e012e44
Autor:
Hong Zheng, Xiaoqing Yu, Mohammed L. Ibrahim, Dana Foresman, Mengyu Xie, Joseph O. Johnson, Theresa A. Boyle, Brian Ruffell, Bradford A. Perez, Scott J. Antonia, Neal Ready, Andreas N. Saltos, Mark J. Cantwell, Amer A. Beg
Publikováno v:
Cancer Immunology Research. 11:466-485
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membran
Autor:
Alexandra L. Martin, Chase Powell, Mate Z. Nagy, Patrick Innamarato, John Powers, Derek Nichols, Carmen M. Anadon, Ricardo A. Chaurio, Sungjune Kim, Min-hsuan Wang, Bing Gong, Xianzhe Wang, Thomas J. Scheutz, Scott J. Antonia, Jose R. Conejo-Garcia, Bradford A. Perez
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1445-1460
Autor:
Ning Wu, Wenzhen Ge, Ruben GW Quek, Michelle Gleeson, Jean-Francois Pouliot, Hilary Dietz, Jessica J Jalbert, James Harnett, Scott J Antonia
Publikováno v:
Future Oncology. 18:4385-4397
Background: Trends/outcomes associated with National Comprehensive Cancer Network (NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer (aNSCLC) treatment were assessed. Methods: Patients initiating first-line aNSCLC treat
Autor:
Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Abstract Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable respon
Externí odkaz:
https://doaj.org/article/650b58462e0a46c6a4a982d979b2522c